Daiichi Sankyo Company, Limited

Mie University

Daiichi Sankyo Europe Gmbh

Sankto Company, Limited

Ichiro Watanabe

Toshiaki Ohtsuka

Masato Amano

Kazuki Satoh

Kazuki Hirahara

Kensuke Nakamura

Ryuji Hashimoto

Hiroshi Shiku

Makiko Nakayama

Naoya Shinozaki

Kento Tanaka

Yasushi Akahori

Shiho Kozuma

Junya Ichikawa

Ayaka Yatsu

Shinji Furuzono

Tohru Takahashi

Eisuke Tsuda

Keisuke Fukuchi

Yoshiharu Hiruma

Toshinori Agatsuma

Nobufusa Serizawa

Tatsuji Matsuoka

Reimar Abraham

Ingrid Schuster

Dirk Ponsel

Sandra Miller

Ulrike Schubert

Robert Mühlbacher

Kathrin-Ladetzki Baehs

Tanja Lange

Steffen Runz

Johannes Bange

Shinko Hayashi

An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Bispecific antibody

The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Anti-GARP antibody

A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Anti-garp antibody

The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.

Human anti-FGFR4 antibody

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Antibody targeting osteoclast-related protein Siglec-15

A 1 kbp length of the 5'-noncoding region of the gene encoding cytochrome P-450.sub.sca-2 in the actinomycete Streptomyces carbophilus has transcription promoter activity which is substrate inducible. When the 1 kbp region is shortened, transcription activity becomes constitutive and the shortened promoters can be used advantageously in expression systems, especially those expressing P-450.sub.sca-2 in the presence of ML-236B to produce pravastatin sodium.

Actinomycete promoter

Growing community of inventors

Tokyo, Japan

Ichiro Watanabe